Rx Item-Ozurdex 0.7Mg Implant 1 By Allergan Pharma

OZURDEX - dexamethasone implant
Allergan, Inc.

1 INDICATIONS AND USAGE

1.1 Retinal Vein Occlusion
OZURDEX � (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

1.2 Posterior Segment Uveitis
OZURDEX � is indicated for the treatment of non-infectious uveitis affecting the posterior segment of the eye.

​1.3 Diabetic Macular Edema


​OZURDEX � is indicated for the treatment of diabetic macular edema.

2 DOSAGE AND ADMINISTRATION

2.1 General Dosing Information
For ophthalmic intravitreal injection.

2.2 Administration
The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide applied to the periocular skin, eyelid and ocular surface are recommended to be given prior to the injection.

Remove the foil pouch from the carton and examine for damage. Then, open the foil pouch over a sterile field and gently drop the applicator on a sterile tray. Carefully remove the cap from the applicator. Hold the applicator in one hand and pull the safety tab straight off the applicator. Do not twist or flex the tab. The long axis of the applicator should be held parallel to the limbus, and the sclera should be engaged at an oblique angle with the bevel of the needle up (away from the sclera) to create a shelved scleral path. The tip of the needle is advanced within the sclera for about 1 mm (parallel to the limbus), then re-directed toward the center of the eye and advanced until penetration of the sclera is completed and the vitreous cavity is entered. The needle should not be advanced past the point where the sleeve touches the conjunctiva.

Slowly depress the actuator button until an audible click is noted. Before withdrawing the applicator from the eye, make sure that the actuator button is fully depressed and has locked flush with the applicator surface. Remove the needle in the same direction as used to enter the vitreous.

Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay.

Each applicator can only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new applicator must be used, and the sterile field, syringe, gloves, drapes, and eyelid speculum should be changed before OZURDEX � is administered to the other eye.

3 DOSAGE FORMS AND STRENGTHS

Intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR � solid polymer drug delivery system.

RX ITEM-Ozurdex 0.7Mg Implant 1 By Aller
NDC 00023-3348-07 UPC/GTIN No.3-00233-34807-9 Mfg.Part No.334807

Ozurdex 0.7Mg Implant 1 By Allergan Phar
BRAND: OZURDEX NDC: 00023-3348-07,23334807 UPC: 3-00233-34807-9,300233348079 Allergan USA, Inc.

DEXAMETHASONE INTRAOCULR
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

Ozurdex 0.7mg Implant 1 by All
Ozurdex 0.7mg Implant 1 by Allergan Pharma

Ozurdex 0.7mg Implant 1 by All
Ozurdex 0.7mg Implant 1 by Allergan Pharma